BridgeBio’s heart drug misses primary focus of pivotal study

A The treatment developed by BridgeBio for increasingly common heart disease has missed its primary endpoint in a closely watched trial, the company said on Monday, derailing its plans and prolonging the development of what experts saw as a promising new drug.

Patients treated with the drug, called acoramidis, did not perform better than a placebo in a test of how far they could walk in six minutes. BridgeBio has recruited approximately 600 patients with ATTR-CM, a progressive heart disease. After 12 months, patients with acoramidis could walk nine meters less, and patients on placebo walked seven meters less.

Unlock this article by subscribing to STAT + and enjoy your first 30 days free!

TO START

What is that?

STAT + is STAT’s premium subscription service for in-depth coverage and analysis of biotechnology, pharmaceuticals, policy and life sciences. Our award-winning team covers news on Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, as well as healthcare disruptions in Silicon Valley and beyond.

What is included?

  • Daily reporting and analysis
  • Industry’s most comprehensive coverage from a powerful team of journalists
  • Newsletters reserved for subscribers
  • Daily newsletters to keep you informed of the most important industry news of the day
  • STAT + conversations
  • Weekly opportunities to engage with our journalists and leading industry experts in live video chats
  • Exclusive industry events
  • Premium access to subscriber-only networking events nationwide
  • The best reporters in the industry
  • The most trusted, connected newsroom in healthcare
  • And much more
  • Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.
Source link

About Michael Bill

Check Also

The reason Neil Young struggles to perform live

Just as Neil Young began to find his way in the world as an aspiring …